SecProbe.io

CORRESP
1
filename1.htm

February 7, 2023

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Industrial Applications and Services

100 F Street, NE

Washington, D.C. 20549

    Attention:
    Margaret Schwartz

    Laura Crotty

    Tracie Mariner

    Al Pavot

    Re:
    Nava Health MD, LLC

    Amendment No. 1 to Registration Statement on Form S-1

    Filed January 30, 2023

    File No. 333-268022

Dear Ms. Schwartz:

On behalf of Nava Health MD,
LLC, a Delaware limited liability company (the “Company”), we are responding to the comments from the Staff (the “Staff”)
of the Securities and Exchange Commission (the “Commission”) dated February 1, 2023 (the “Comment Letter”),
regarding the abovementioned Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-268022) filed by the Company
on January 30, 2023 (the “Amendment”). In response to the comments set forth in the Comment Letter, the Company
has updated the Amendment and is concurrently submitting the updated Amendment with this response letter. The updated Amendment also contains
certain additional updates and revisions.

Set forth below are the Company’s
responses to the Staff’s comments. For convenience, the Staff’s comments are restated below in bold text, with each comment
followed by the Company’s response. We have included page numbers to refer to the location in the Amendment, filed on the date
hereof, where the revised language addressing a particular comment appears. Capitalized terms used, but not defined, in this letter have
the meanings ascribed to such terms in the Amendment.

Amendment No. 2 to Registration Statement
on Form S-1, Filed January 30, 2023

Risk Factors, Page 11

 1. We note recent instances of extreme stock price run-ups followed by rapid price declines and stock price volatility seemingly unrelated
to company performance following a number of recent initial public offerings, particularly among companies with relatively smaller public
floats. Revise to include a separate risk factor addressing the potential for rapid and substantial price volatility and any known factors
particular to your offering that may add to this risk and discuss the risks to investors when investing in stock where the price is changing
rapidly. Clearly state that such volatility, including any stock-run up, may be unrelated to your actual or expected operating performance
and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of your stock.

Response:
In response to the Staff’s comment, the Company has revised its disclosure on page [36] to include a separate risk factor addressing
the potential for rapid and substantial price volatility.

Nava Health MD, LLC

February 7, 2023

Page 2

Use of Proceeds, page 42

 2. We note in your free writing prospectus filed January 30, 2023, you state that one of your uses of proceeds for this offering
is strategic acquisitions. Please revise the Registration Statement to reflect this or advise.

Response:
The Company acknowledges the Staff’s comment and advises the Staff that strategic acquisitions as a use of proceeds from the Offering
was inappropriately included in the free writing prospectus filed January 30, 2023 and such reference has been removed.

If you have any questions
or require additional information, please contact the Company’s counsel, Rachel M. Jones at (410) 528-4652 or at rmjones@venable.com
or Eric R. Smith at (410) 528-2355 or at ersmith@venable.com, of Venable LLP.

    Sincerely,

    By:
    /s/ Eric Smith

    cc:
    Bernaldo Dancel, Nava Health MD, LLC

    Chien-Chien Jacques, Nava Health MD, LLC

    Rachel Jones, Esq., Venable LLP